BioDelivery Sciences International, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Herm Cukier
- Full Time Employees
- 200
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4131 Parklake Ave Ste 225 Raleigh NC United States of America 27612
- IPO Date
- Jul 25, 2002
- CIK
- 0001103021
- Website
- bdsi.com
- Similar Companies
- Business
- BioDelivery Sciences International, Inc. BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company founded in 1997 and headquartered in Raleigh, North Carolina, develops and commercializes pharmaceutical products utilizing its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology, which employs small erodible polymer films for rapid transmucosal drug delivery targeting chronic conditions. The company focuses on areas such as addiction medicine, chronic pain management, and opioid dependence, offering key marketed products including BELBUCA (buprenorphine buccal film) for chronic pain; Symproic (naldemedine) for opioid-induced constipation in adults with chronic non-cancer pain; ELYXYB (celecoxib oral solution) for acute migraine treatment in adults; and ONSOLIS (fentanyl buccal soluble film) for breakthrough cancer pain. It operates primarily in the United States through its own commercial infrastructure while pursuing partnerships for international commercialization, serving patients with serious and debilitating conditions including those related to prior cancer treatment. In March 2022, BioDelivery Sciences International was acquired by Collegium Pharmaceutical, Inc. Collegium Pharmaceutical, Inc. in an all-cash transaction valued at approximately $604 million, integrating its pain and neurology portfolio—including BELBUCA as a complementary Schedule III opioid product—into Collegium's offerings and enabling rapid synergies in chronic pain and adjacent neurology markets. Post-acquisition, the BEMA technology and product lines continue to support Collegium's expanded specialty pharmaceutical operations, with no significant further structural changes reported as of 2025.
Has BioDelivery Sciences International (BDSI) Outpaced Other Medical Stocks This Year?
Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline
BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?
BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium
BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today
3 Potential Value Opportunities to Consider
Trading Penny Stocks? Top Stock Market News for February 14th, 2022
BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium
Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)
Why Shares of BioDelivery Sciences International Jumped 12.2% on Monday
Best Penny Stocks to Buy During The Down Market? 3 to Watch
These 3 Penny Stocks Exploded Today, Here's Why
BioDelivery (BDSI) Stock Up on Raised Guidance for 2021
BioDelivery Sciences Stock (BDSI): Why The Price Surged Today
Why BioDelivery Sciences International Stock Was Up 28.5% Monday
Making a List of Penny Stocks to Buy? Check These 3 Out Right Now
Hot Penny Stocks To Buy For Under $5 Right Now
Why Is BioDelivery (BDSI) Down 20.8% Since Last Earnings Report?
Best Reddit Penny Stocks to Buy Now? 4 to Watch in Mid-November
BioDelivery Sciences International's (BDSI) CEO Jeff Bailey on Q3 2021 Results -Earnings Call Transcript